Journal Article

Ocular toxicities of MEK inhibitors and other targeted therapies

N. Stjepanovic, J. P. Velazquez-Martin and P. L. Bedard

in Annals of Oncology

Published on behalf of European Society for Medical Oncology

Volume 27, issue 6, pages 998-1005
Published in print June 2016 | ISSN: 0923-7534
Published online March 2016 | e-ISSN: 1569-8041 | DOI: https://dx.doi.org/10.1093/annonc/mdw100
Ocular toxicities of MEK inhibitors and other targeted therapies

Show Summary Details

Preview

Many classes of anticancer therapy, including chemotherapeutic agents, hormonal and molecular targeted treatments, can produce ocular toxicity. Novel agents that target different cellular pathways have been related to a wide spectrum of ophthalmologic toxicities that can range from mild to severe, and include conjunctivitis, blurred vision, keratitis and optic neuritis, among others. Special attention has been drawn to the inhibitors of the MEK signaling pathway, due to their sine qua non ocular toxicity, defined as MEK retinopathy and described as symmetrical bilateral disease that develops in a time-dependent and dose-dependent manner. In this review, we discuss ophthalmologic toxicities associated with molecular targeted therapies, with particular focus on MEK retinopathy, including its nomenclature, incidence, symptoms and management.

Keywords: ocular toxicity; antineoplastic agents; mitogen-activated protein kinase; MEK retinopathy; targeted therapies

Journal Article.  6849 words.  Illustrated.

Subjects: Medical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or purchase to access all content.